Palla Pharma Ltd
ASX:PAL
Palla Pharma Ltd
ASX:PAL
Price:
0.295 AUD
Market Closed
Updated:
May 20, 2024
EV/OCF
Enterprise Value to OCF
Enterprise Value to OCF
-2.1
Current
-2.1
Median
20.9
Industry
Higher
than median
Lower
than industry value
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
EV/OCF
=-2.1
Enterprise Value
/
47.4m
Operating Cash Flow
-22.7m
All Countries
| Market Cap | EV/OCF | ||||
|---|---|---|---|---|---|
| AU |
|
Palla Pharma Ltd
ASX:PAL
|
47.8m AUD | -2.1 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
226.8B USD | 28.1 | |
| US |
|
Danaher Corp
NYSE:DHR
|
198B USD | 29.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
45.3B USD | 23.5 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
38.2B CHF | 28.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.8B USD | 24.8 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
56.2T KRW | 33.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
32.4B USD | 34.1 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
26.4B USD | 22.4 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
25.1B USD | 32.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
21B USD | 33.9 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A
You don't have any saved screeners yet
